Abbott Uses AI for Atrial Fibrillation Detection
Abbott Laboratories has introduced its Assert-IQ insertable cardiac monitor (ICM) system, which employs artificial intelligence to detect and classify atrial fibrillation (AFib) in near real-time. The technology aims to improve diagnostic accuracy and patient care.
Abbott's Assert-IQ System Leverages AI for Early AFib Detection
Abbott Laboratories has implemented its Assert-IQ insertable cardiac monitor (ICM) system, integrating artificial intelligence (AI) for the detection of atrial fibrillation (AFib), a common heart rhythm disorder. The system combines advanced cardiac monitoring technology on the device with cloud-based AI algorithms to identify and classify AFib episodes in near real-time.
AFib poses risks of serious health complications, including blood clots, stroke, and heart failure, underscoring the importance of early detection and management. The Assert-IQ ICM is a small device inserted subcutaneously for individuals requiring arrhythmia monitoring. It analyzes every heartbeat for up to six years.
The AI algorithm plays a critical role by filtering the significant volume of data collected. Rather than overwhelming healthcare teams with raw data, including potential false positives, the AI identifies AFib episodes and transmits only confirmed events. This process assists physicians in prioritizing information and achieving faster, clearer insights.
Abbott states that the AI-enhanced accuracy of the monitor enables physicians to tailor patient care plans based on the verified data. The goal is to improve the timeliness of AFib diagnosis, thereby enhancing patient outcomes and quality of life.